Patents Assigned to Salk Institute for Biological Studies
  • Patent number: 10774092
    Abstract: In certain aspects, the invention provides a method for treating a disease or condition in a subject, the method comprising co-administering to a subject in need thereof a therapeutically effective amount of at least one ULK1-inhibiting pyrimidine, and a therapeutically effective amount of an mTOR inhibitor.
    Type: Grant
    Filed: April 19, 2019
    Date of Patent: September 15, 2020
    Assignees: SALK INSTITUTE FOR BIOLOGICAL STUDIES, SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE, YALE UNIVERSITY
    Inventors: Reuben J. Shaw, Daniel F. Egan, Nicholas Cosford, Benjamin Turk, Mitchell Vamos, Dhanya Raveendra Panickar, Matthew Chun, Douglas Sheffler
  • Patent number: 10745674
    Abstract: The present invention relates to methods for producing polyketide synthase variants, and for altering the activity and/or substrate specificity of putative native and variant polyketide synthases. The present invention further relates to compositions comprising said polyketide synthase variants, compounds prepared using said polyketide synthase variants, and uses of said polyketide synthase variants. In one embodiment, said polyketide synthase variant is 2-pyrone synthase.
    Type: Grant
    Filed: March 5, 2015
    Date of Patent: August 18, 2020
    Assignees: SALK INSTITUTE FOR BIOLOGICAL STUDIES, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Joseph Noel, Kate Woods, Marianne Bowman, Gordon Louie, Nancy Anderson Da Silva, Javier Pascual Cardenas
  • Patent number: 10738325
    Abstract: Recombinant adenovirus genomes that include an exogenous open reading frame (ORF) and a self-cleaving peptide coding sequence are described. Optimal placement of the exogenous genes for minimal impact on viral kinetics is further disclosed. Therapeutic applications of the recombinant adenoviruses are also described.
    Type: Grant
    Filed: August 23, 2018
    Date of Patent: August 11, 2020
    Assignee: Salk Institute for Biological Studies
    Inventors: Clodagh O'Shea, William Partlo, Colin Powers
  • Patent number: 10738282
    Abstract: The finding that phosphatidylserine (PtdSer) exposure on the outer leaflet of virally transduced cells triggers their engulfment by resident immune cells is described. It is demonstrated that inhibition of phospholipid scramblase 1 (PLSCR1) activity prevents PtdSer externalization and enables prolonged protection of vector-transduced cells from phagocytosis. Methods of inhibiting a virus vector-induced inflammatory response in tissue, methods of prolonging virus vector encoded transgene expression, and methods of modulating an inflammatory response in tissue of a subject, by administering an inhibitor of PLSCR1 are described.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: August 11, 2020
    Assignee: Salk Institute for Biological Studies
    Inventors: Axel Nimmerjahn, Charles L. Clark
  • Publication number: 20200252359
    Abstract: Provided herein are CRISPR/Cas methods and compositions for targeting RNA molecules, which can be used to detect, edit, or modify a target RNA.
    Type: Application
    Filed: March 17, 2020
    Publication date: August 6, 2020
    Applicant: Salk Institute for Biological Studies
    Inventors: Patrick D. Hsu, Silvana Konermann
  • Patent number: 10729790
    Abstract: The present disclosure relates to nucleic acid promoter sequences that are able to specifically express genes operatively linked to the promoter in brainstem and spinal motor neuron cells, and to methods for using such promoters to selectively express genes in motor neurons in vitro and in vivo. It is based, at least in part, on the discovery that the nucleic acid of SEQ ID NO: 1 functioned as a motor neuron-specific promoter and was successful in expressing transgenes in motor neuron cells in vivo. The present disclosure also relates to compositions that can increase the activity or expression level of miR-218 and to compositions that can decrease the expression of miR-218 target nucleic acids.
    Type: Grant
    Filed: May 24, 2016
    Date of Patent: August 4, 2020
    Assignee: SALK INSTITUTE FOR BIOLOGICAL STUDIES
    Inventor: Neal Dilip Amin
  • Publication number: 20200244609
    Abstract: Provided herein are CRISPR/Cas methods and compositions for targeting RNA molecules, which can be used to detect, edit, or modify a target RNA.
    Type: Application
    Filed: January 30, 2020
    Publication date: July 30, 2020
    Applicant: Salk Institute for Biological Studies
    Inventors: Patrick D. Hsu, Silvana Konermann
  • Publication number: 20200216490
    Abstract: Provided herein are deuterated compounds and compositions useful in increasing PPAR? activity. The compounds have a formula where L5 comprises at least one deuterium. Exemplary species include The compounds and compositions provided herein are useful for the treatment of PPAR? related diseases (e.g., muscular diseases, vascular disease, demyelinating disease, and metabolic diseases).
    Type: Application
    Filed: December 17, 2019
    Publication date: July 9, 2020
    Applicant: The Salk Institute for Biological Studies
    Inventors: Ronald M. Evans, Michael Downes
  • Patent number: 10695404
    Abstract: Methods of using FGF1 analogs, such as FGF1 mutant proteins having an N-terminal deletion, point mutation(s), or combinations thereof, to reduce blood glucose levels in subjects with steroid-induced diabetes, hypercortisolemia, or diabetes due to treatment with an antipsychotic agent, are provided. Such mutant FGF1 proteins can be part of a chimeric protein that includes a ?-Klotho-binding protein, an FGFR1-binding protein, a ?-Klotho-binding protein and a FGFR1-binding protein, a C-terminal region from FGF19 or FGF21.
    Type: Grant
    Filed: April 13, 2018
    Date of Patent: June 30, 2020
    Assignee: Salk Institute for Biological Studies
    Inventors: Ronald M. Evans, Michael Downes, Annette Atkins, Ruth T. Yu
  • Publication number: 20200199556
    Abstract: Provided herein are CRISPR/Cas methods and compositions for targeting RNA molecules, which can be used to detect, edit, or modify a target RNA.
    Type: Application
    Filed: February 21, 2020
    Publication date: June 25, 2020
    Applicant: Salk Institute for Biological Studies
    Inventors: Patrick D. Hsu, Silvana Konermann
  • Patent number: 10689397
    Abstract: In certain aspects, the invention provides a method for treating a disease or condition in a subject, the method comprising co-administering to a subject in need thereof a therapeutically effective amount of at least one ULK1-inhibiting pyrimidine, and a therapeutically effective amount of an mTOR inhibitor.
    Type: Grant
    Filed: February 6, 2019
    Date of Patent: June 23, 2020
    Assignees: SALK INSTITUTE FOR BIOLOGICAL STUDIES, SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE, YALE UNIVERSITY
    Inventors: Reuben J. Shaw, Daniel F. Egan, Nicholas Cosford, Benjamin Turk, Mitchell Vamos, Dhanya Raveendra Panickar, Matthew Chun, Douglas Sheffler
  • Publication number: 20200190019
    Abstract: Provided herein are compounds and compositions useful in increasing PPAR? activity. The compounds and compositions provided herein are useful for the treatment of PPAR? related diseases (e.g., muscular diseases, vascular disease, demyelinating disease, and metabolic diseases).
    Type: Application
    Filed: December 16, 2019
    Publication date: June 18, 2020
    Applicants: Salk Institute for Biological Studies, Mitobridge, Inc.
    Inventors: Ronald M. Evans, Michael Downes, Thomas J. Baiga, Joseph P. Noel, Emi Kanakubo Embler, Weiwei Fan, John F.W. Keana, Mark G. Bock, Authur F. Kluge, Mike A. Patane
  • Patent number: 10666592
    Abstract: Provided herein are CRISPR/Cas methods and compositions for targeting RNA molecules, which can be used to detect, edit, or modify a target RNA.
    Type: Grant
    Filed: December 31, 2018
    Date of Patent: May 26, 2020
    Assignee: Salk Institute for Biological Studies
    Inventors: Patrick D. Hsu, Silvana Konermann
  • Publication number: 20200149014
    Abstract: Methods of assembling modified adenoviruses, libraries of adenoviral gene modules and compositions thereof are provided herein.
    Type: Application
    Filed: January 22, 2020
    Publication date: May 14, 2020
    Applicant: Salk Institute for Biological Studies
    Inventors: Clodagh O'Shea, Colin Powers
  • Publication number: 20200141947
    Abstract: The invention features compositions and methods treating or preventing for age-related insulin resistance, type 2 diabetes and related disorders. The method involves depleting fTreg cells with an anti-ST2 antibody to decrease age-related fTreg accumulation and restore insulin sensitivity, thereby treating age-related insulin resistance, type 2 diabetes and related disorders.
    Type: Application
    Filed: December 4, 2019
    Publication date: May 7, 2020
    Applicant: SALK INSTITUTE FOR BIOLOGICAL STUDIES
    Inventors: SAGAR P. BAPAT, YE ZHENG, RONALD EVANS, MICHAEL DOWNES, ANNETTE R. ATKINS, RUTH T. YU
  • Publication number: 20200129532
    Abstract: Methods are provided for reducing blood glucose, which utilize an agent that increases the biological activity of a vitamin D receptor (VDR) (e.g., a VDR agonist), in combination with an antagonist of bromodomain-containing protein 9 (BRD9). IN some examples, such methods treat type II diabetes.
    Type: Application
    Filed: January 8, 2020
    Publication date: April 30, 2020
    Applicant: Salk Institute for Biological Studies
    Inventors: Ronald M. Evans, Michael Downes, Zong Wei, Annette Atkins, Ruth T. Yu
  • Publication number: 20200123113
    Abstract: Novel compounds having a formula embodiments of a method of making the same, and of a composition comprising them are disclosed herein. Also disclosed are embodiments of a method of treating or preventing a metabolic disorder in a subject, comprising administering to a subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and treating or preventing a metabolic disorder in the subject. Additionally disclosed are embodiments of a method of treating or preventing inflammation in an intestinal region of a subject, comprising administering to the subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and thereby treating or preventing inflammation in the intestinal region of the subject.
    Type: Application
    Filed: September 10, 2019
    Publication date: April 23, 2020
    Applicants: Salk Institute for Biological Studies, The University of Sydney
    Inventors: Ronald M. Evans, Michael Downes, Annette Atkins, Sungsoon Fang, Jae Myoung Suh, Thomas J. Baiga, Ruth T. Yu, John F.W. Keana, Christopher Liddle
  • Publication number: 20200127954
    Abstract: Provided herein are CRISPR/Cas methods and compositions for targeting RNA molecules, which can be used to detect, edit, or modify a target RNA.
    Type: Application
    Filed: December 31, 2018
    Publication date: April 23, 2020
    Applicant: Salk Institute for Biological Studies
    Inventors: Patrick D. Hsu, Silvana Konermann
  • Patent number: 10577589
    Abstract: Methods of assembling modified adenoviruses, libraries of adenoviral gene modules and compositions thereof are provided herein.
    Type: Grant
    Filed: November 9, 2015
    Date of Patent: March 3, 2020
    Assignee: Salk Institute for Biological Studies
    Inventors: Clodagh O'Shea, Colin Powers
  • Publication number: 20200040051
    Abstract: The present disclosure provides FGF1 mutant proteins having one or more mutations in the heparin binding domain. Such mutants may also have an N-terminal deletion, point mutation(s), or combinations thereof. In some examples, the mutant FGF1 proteins have reduced mitogenic activity. Also provided are nucleic acid molecules that encode such proteins, and vectors and cells that include such nucleic acids. The disclosed FGF1 mutants can reduce blood glucose in a mammal, and in some examples are used to treat a metabolic disorder.
    Type: Application
    Filed: October 24, 2019
    Publication date: February 6, 2020
    Applicants: Salk Institute for Biological Studies, The Florida State University Research Foundation, Incorporated
    Inventors: Ronald M. Evans, Michael Downes, Annette Atkins, Ruth T. Yu, Michael Blaber, Xue Xia